Table 1 Literature regarding the influence of morbidity on long-term survival after resection of colorectal cancer from 2004 to 2017

Law et al. [31] 2004, Hong Kong

40 (3–109)^a

AL versus No AL

NA

6

6

8/30 vs 156/533, p = 0.7600

R

p = 0.004

Eriksen et al. [32] 2004, Norway

45 (0–98)^a

AL versus No AL

6 (117/1958)

NA

22 (T4)

93/228 vs 564/1730, p = 0.014

R

NA

Walker et al. [33] 2004, Australia

≥60^a

AL versus No AL

NA

NA

5

44.3% vs 64%, p = 0.0001

R/C

1.6 (CI 1.3–2.1)

Nespoli et al. [34] 2004, Italy

≥60^a

Yes, versus No

NA

NA

NA

p = 0.0006

C

NA

Branagan and Finnis et al. [35] 2005, UK

≥60^a

AL versus No AL

NA

NA

4

R: 17/36 vs 210/581, p = 0.1840

C: 9/22 vs 430/112, p = 0.8100

R/C

NA

McArdle et al. [36] 2005, UK

≥60^a

AL versus No AL

NA

NA

4

43/86 vs 688/2149, p = 0.0010

R/C

1·61 (CI 1·19, 2·16)

Ptok et al. [37] 2007, Germany

≥40^a

AL versus No AL

50 for (AL group)

26 (for Non-AL group)

15

74/255 vs 337/1370, p = 0.1360

R

NA

Law et al. [22] 2007, Hong Kong

46^c

Yes, versus No

NA

27

4

26/60 vs 366/1520, p = 0.0010

R/C

1.26, p = 0.023

Lee et al. [38] 2008, Korea

44.6 (2–157)^a

AL versus No AL

73 (933/1278) (T3/T4)

NA

4

80.2% vs 64.9%, p = 0.17

R

NA

Eberhardt et al. [34] 2009, USA

≥60^a

AL versus No AL

NA

NA

33

13/59 vs 16/118, p = 0.1550

R/C

NA

Den Dulk et al. [39] 2009, Multinational

70.8 (2–179)^a

AL versus No AL

NA

NA

10

46/220 vs 427/2199, p = 0.5950

R

1.48

Bertelsen et al. [40] 2009, Denmark

45.2 (1–74)^a

AL versus No AL

NA

NA

11

50/357 vs 95/1077, p = 0.005

R

1.63 (CI 1.21–2.19)

Jogren et al. [41] 2009, Sweden

60^c

AL versus No AL

10 (25/250)

NA

NA

63% vs 66%, p = 0.38

R

1

Mirnezami et al. [42] 2011, UK

–

AL versus No AL

–

–

–

R/C

1.75 (CI 1.47–2.1), p = 0.0001

Gooiker et al. [43] 2012, Netherland

48^c

Yes, versus No

NA

20

NA

12% vs 26%, p = 0.02 (1 year)

R/C

5.9 (CI 1.3–26.8)

Smith et al. [28] 2013, USA

35^c

AL versus No AL

7

11

32 vs 72%, p = 0.01

R

NA

Henneman et al. [44] 2014, Netherland

NA

Yes, versus No

NA

NA

C: 27

R: 36.5

NA

R/C

NA

Odermatt et al. [45] 2015, UK

≥60^a

AL versus No AL

10 (84/844)

5

3

p = 0.80

R/C

1.04 (CI 0.76–1.42)

Ebinger et al. [46] 2015, Germany

62 (2–254)^a

AL versus No AL

NA

NA

11

p = 0.701

R

0.91 (CI 0.56–1.47)

Kulu et al. [30] 2015, Switzerland

56 ± 35^b

AL versus No AL

NA

NA

9

65% vs 83%

R

2.27 (CI 1.33–3.88), p = 0.005

Hain et al. [29] 2016, France

40 ± 27^b

AL versus No AL

50 (214/428) (pT3/T4)

50

28

78·6% vs 88·4%, p = 0.001

R

NA

Breugom et al. [47] 2016, Netherland

64.8 (56.4–74.4)^a

Yes, versus No

75 (570/761) (T3/T4)

42

5

65% vs 35%, p = 0.001

C

1.59 (CI 1.25–2.04), p = 0.001

Jamnagerwalla et al. [48] 2016, Australia

46^c

Chemotherapy versus No Chemotherapy

100 (517/517) (T3/T4)

28

3.5

NA

R

0.53, p = 0.04

Nordholm-Carstensen et al. [49] 2017, Denmark

37 (25–50)^a

Yes, versus No

NA

NA

9

C: 18.7% vs 44.6% p < 0.001

R: 53.7% vs 73.3% p = 0.0600

R/C

C: 1.67 (CI 1.03–2.68), p = 0.04

R: 0.93 (CI 0.24–3.57), p = 0.91

Present study 2017, France

42

Yes, versus No

100 (106/106)

43

4

65% vs. 69%; p = 0.72

R/C

p > 0.05